From the Vascular Biology Research Group, John P. Robarts' Research Institute, the § Division of
Cardiology, London Health Sciences Center, University Hospital, and
the ¶ Department of Microbiology and Immunology, University of
Western Ontario, London, Ontario N6A 5K8, Canada
Received for publication, September 20, 2002, and in revised form, March 7, 2003
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Complex DNA viruses have tapped into cellular
serpin responses that act as key regulatory steps in coagulation and
inflammatory cascades. Serp-1 is one such viral serpin that effectively
protects virus-infected tissues from host inflammatory responses. When given as purified protein, Serp-1 markedly inhibits vascular monocyte invasion and plaque growth in animal models. We have investigated mechanisms of viral serpin inhibition of vascular inflammatory responses. In vascular injury models, Serp-1 altered early cellular plasminogen activator (tissue plasminogen activator), inhibitor (PAI-1), and receptor (urokinase-type plasminogen activator) expression (p < 0.01). Serp-1, but not a reactive center loop
mutant, up-regulated PAI-1 serpin expression in human endothelial
cells. Treatment of endothelial cells with antibody to urokinase-type
plasminogen activator and vitronectin blocked Serp-1-induced changes.
Significantly, Serp-1 blocked intimal hyperplasia (p < 0.0001) after aortic allograft transplant (p < 0.0001) in PAI-1-deficient mice. Serp-1 also blocked plaque growth
after aortic isograft transplant and after wire-induced injury
(p < 0.05) in PAI-1-deficient mice indicating that
increase in PAI-1 expression is not required for Serp-1 to block
vasculopathy development. Serp-1 did not inhibit plaque growth in
uPAR-deficient mice after aortic allograft transplant. We conclude that
the poxviral serpin, Serp-1, attenuates vascular inflammatory responses
to injury through a pathway mediated by native uPA receptors and vitronectin.
An integrated balance between the thrombotic and thrombolytic
cascades, both of which are regulated by serine proteinases, activates
arterial clot formation and also mediates inflammatory cell responses
at sites of vascular injury (1-7). Serine proteinase inhibitors,
termed serpins, in turn regulate these cascades (7). Larger DNA
containing viruses have captured host serpins during millions of years
of evolution, and adapted them into highly effective shields against
host inflammatory responses (8). Serp-1, a secreted anti-inflammatory
protein encoded by myxoma virus, is one such poxviral serpin that binds
and inhibits, in vitro, the thrombolytic serine proteinases
tissue-type and urokinase-type plasminogen activators
(tPA1 and uPA, respectively)
and plasmin (9, 10). In vivo, Serp-1 reduces inflammatory
leukocyte responses to myxoma viral infection (9, 10). Furthermore,
infusion of picogram to nanogram doses of purified Serp-1 protein also
profoundly inhibits monocytic cell invasion and subsequent
atherosclerotic plaque growth following vascular injury induced by
angioplasty (11) or allograft transplant (12,
13)2 in animal models, thus
providing a new class of anti-inflammatory drugs.
The precise targets and/or receptors, through which viral serpins,
specifically Serp-1, inhibit inflammatory cell responses are not yet
defined (10-17). uPA, when bound to the uPA receptor (uPAR),
enhances inflammatory cell migration (3, 4, 7, 17, 18), cell adhesion
mediated by vitronectin (3, 19, 21), cell invasion through activation
of matrix metalloproteinase enzymes (20, 22), and the release
and activation of growth factors (23). Serpins, inhibit individual
steps in these cascades through directed one-to-one stoichiometric
inhibition of many of these enzymes (3-7, 23-25). PAI-1 is a
naturally occurring vascular serpin that, like Serp-1, binds to uPA and
tPA in the circulating blood, inhibiting plasminogen activator
activity, but, in contrast to Serp-1, does not inhibit plasmin activity (8, 21-27). Plasminogen activator inhibitor-1 (PAI-1)-deficient mice
have significantly increased intimal hyperplasia after arterial injury
(26-28). This injury induced intimal hyperplasia is reduced by
administration of adenoviral vectors expressing PAI-1, suggesting that
PAI-1 together with the plasminogen system acts as a central regulator
of vascular wound repair responses (26-28). Recent work has
demonstrated accelerated lesion growth in carotid arteries of
cholesterol fed rabbits with overexpression of uPA (29) and reduced
plaque after arterial injury in uPA and plasminogen-deficient mice (30,
31) confirming a pro-atherogenic role for uPA in these animal models.
Other studies have been less conclusive, demonstrating either
pro-atherogenic or thrombotic effects, for plasminogen and plasmin
inhibitors in animal models (32, 33). Injury to the arteries of
uPAR-deficient mice has not, however, been found to alter plaque
development (26).
PAI-1 forms ternary complexes together with uPA and its receptor, uPAR
(3-6, 34, 35). This ternary complex is rapidly internalized,
effectively blocking the pro-chemotactic, adhesive, and proteolytic
activity of the uPA·uPAR complex. The uPA·uPAR complex interacts
with the We have postulated that Serp-1 interacts with the uPA/uPAR pathway, to
inhibit inflammatory responses to arterial injury (11-14). We
initially examined uPAR-linked regulation of vascular and endothelial cell serpin expression following Serp-1 treatment after arterial injury
in rat models. Based on those studies, we subsequently examined the
effect of Serp-1 infusion on plaque growth after aortic transplant in
mouse knockouts deficient in PAI-1 or uPAR. The capacity of Serp-1 to
inhibit plaque growth differed dramatically when the PAI-1-
(PAI-1 Animal Models of Arterial Surgery
General Surgical Method--
All research protocols and animal
care conformed to the Guiding Principles for Animal Experimentation of
the Canadian Council on Animal Care. Surgeries were performed under
general anesthetic (6.5 mg per 100 g of body weight intra-muscular
injection of Somnotrol, MTC Pharmaceuticals, Cambridge, Canada). Serp-1
or controls (1.0 ml volume/rats, 0.2 ml/mice) were given by
intra-arterial injection through the central balloon lumen immediately
after balloon or wire injury and by venous injection (penile vein) for
aortic allograft transplant surgery. Animals were sacrificed with
euthanyl (Bimeda-MTC Animal Health Ltd., Cambridge, Ontario,
Canada), 0.05 ml for mice and 0.25 ml for rats given
intramuscularly. No increase in mortality was detected for any
of the rats with angioplasty injury or mice after aortic transplant
using either PAI-1- or uPAR-deficient mouse strains (p = 0.49). Serp-1 infusion did not result in any increase in adverse
events or mortality.
Rat Angioplasty Injury Model--
In Study 1 (Table
I) we analyzed the effects of either 30 ng (per animal) of Serp-1 purified from vaccinia vector (Serp-1 VV) (11) or isolated from Chinese hamster ovary (CHO) cells (Serp-1
CHO) (13, 14), the Serp-1 reactive center loop mutant (SAA) (11, 14),
or saline (Fig. 1) infusion on intimal hyperplasia after ilio-femoral
angioplasty balloon injury in 30 Sprague-Dawley rats (250-350 g,
Charles River Laboratories, Wilmington, MA) at 28 days (11, 14). In
Study 2 (Table I, 207 rats), 120 rats were treated with
either Serp-1 CHO (60 rats) or saline (60 rats) and mRNA levels of
tPA, uPA, PAI-1, and uPAR were analyzed by semi-quantitative RT-PCR
analysis in rat arteries at 0, 4, 12, and 24 h and 10 days after
angioplasty injury (12 rats/treatment group/time). A subset of 21 rats
had arterial injury with Serp-1 CHO (12 rats) or saline (9 rats)
treatment for real time PCR analysis. A set of 30 rats treated with
saline, rat PAI-1, SAA, or Serp-1 CHO infusion were sacrificed at
12 h (Table I). Thirty-six rats were sacrificed at 0, 12, and
24 h after Serp-1 or saline infusion without angioplasty injury (6 rats/treatment group). In Study 3, 48 rats treated with
either 30 ng of Serp-1 CHO (6 rats) or saline (6 rats) were sacrificed
at 0, 12, and 24 h and 28 days after angioplasty for analysis of
tPA and PAI-1 protein expression and enzyme activity. All rats were
maintained on a normal rat diet.
Mouse Aortic Allograft Transplant Model--
We performed
segmental 0.3-cm aortic isograft and allograft transplantation (12, 37)
using all combinations of Balb/c (PAI-1+/+), C57Bl/6
(PAI-1+/+), and C57Bl/6J (PAI-1 Mouse Femoral Arterial Wire Injury Model--
We performed wire
injury in the femoral artery of 12 C57Bl/6J PAI-1 Histological, Immunohistochemical, and Morphometric Analysis
Arterial sections, 3.0 cm in length, were harvested from the
distal abdominal aorta just proximal to the iliac bifurcation to the
femoral branch from each rat in Study 1, cut into three 1.0-cm lengths, sectioned, and stained with hematoxylin and eosin for
morphometric analysis of plaque area (11-14). Two 5-µm sections were
cut and stained for each of the 3 arterial sections from each rat (a
total of 6 sections was examined for each artery). Aortic transplant
artery specimens or femoral arterial wire-injured arterial specimens,
0.5-0.6 cm in length, from the mice were cut into two 0.25-0.3-cm
long sections and two 5-µm sections were cut from each specimen for
histological analysis. Morphometric analysis was used to measure plaque
area, using sections with the largest detectable area, by means of the
Empix Northern Eclipse trace application program (Empix Imaging Inc.,
Mississauga, Ontario, Canada) using a Sony Power HAD3CCD color video
camera attached to the microscope and calibrated to the microscope
objective (11, 12, 14). The mean total cross-sectional area of the
intima was calculated for each arterial specimen.
Cell Culture and Preparation
Human umbilical vein endothelial (HUVEC, CC-2519 Clonetics,
Walkersville, MD, passages 2-5), rat aortic smooth muscle (passages 3-5) (39), or THP-1 cells (ATCC TIB 202) were incubated with saline, 4 ng/ml Serp-1, or SAA. Cells were also incubated with 20 µg/ml
anti-human antibodies to uPAR, HUVEC were cultured in EGMTM bullet kit CC-3124 (Clonetics)
medium and isolated at passages 2-5 for all experiments. Rat aortic smooth muscle cells, collected at passages 3-5, were isolated and
grown as previously described (39) in Medium 199 (Sigma) with HEPES (25 mM), and L-glutamine (2 mM)
(Invitrogen). THP-1 cells (ATCC TIB 202) provided by Dr. M. Sandig (Department of Anatomy and Cell Biology, University of Western
Ontario, London, Ontario, Canada) were cultured in RPMI 1640 medium
(Invitrogen) with mercaptoethanol (2 × 10 Expression and Purification of Serp-1 and Serp-1 Chimeras
Serp-1 CHO was purified from the supernatant of a recombinant
CHO cell line (Biogen, Inc., Boston, MA) and Serp-1 VV and SAA were
harvested and purified from Buffalo green monkey kidney cell supernatants as previously described (10-14). SAA was prepared by
mutating the Serp-1 P1-P1' reactive center loop site (R-N) to an A-A
sequence as previously reported (10-12, 14). Serp-1 or SAA proteins
were more than 95% pure as judged by overloaded Coomassie-stained
SDS-PAGE gels and reverse-phase HPLC (11-14). Serp-1 was tested and
found to be free of
endotoxin.3
Analysis of Gene Expression-Reverse Transcriptase and
Northern Blot Analysis
Total RNA was isolated from tissue and cells for (RT-PCR)
analysis using TRIzol reagent (Invitrogen) (40). Preliminary
experiments demonstrated that the amount of tPA, uPA, PAI-1, uPAR, PARs
1-4, and
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2-macroglobulin (low density lipoprotein related protein) receptor at the cellular membrane, an interaction that
is believed to regulate intracellular tyrosine kinase activity (3, 4,
20, 34, 35). This inhibition of the plasminogen activators reduces
activation of the pro-form of matrix metalloproteinase enzymes to
active forms (3-7, 17, 18, 20, 22, 35), thus potentially halting
cellular invasion at sites of vessel trauma. Vitronectin is a
multifunctional adhesion molecule that binds to uPAR forming more
stable PAI-1·uPA·uPAR complexes and has also been reported
to also enhance inhibition of thrombin (34, 36).
/
) and uPAR (uPAR
/
)-deficient
mouse strains were compared, indicating that Serp-1 inhibits
inflammatory cell responses through native vascular uPA receptors.
Delineation of the mechanisms through which viral serpins inhibit
arterial inflammatory responses provides a new approach to the
investigation of inflammatory cell responses and their regulation, both
innate and virally mediated.
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Flow chart for rat iliofemoral angioplasty studies
/
) mice and
similarly C57Bl/6 (uPAR
/
) to Balb/c
(uPAR+/+) (Table II). Mice
were purchased directly from Jackson Laboratories (Bar Harbor, ME).
Sharpoint 11/0 nylon sutures (Surgical Specialties Corporation,
Reiding, MA) were used for end to end aortic anastomosis (12, 14). Mice
were sacrificed at 28 days follow up.
Mouse aortic transplant studies
/
mice
and 6 C57Bl/6 PAI-1+/+ mice although under general
anesthetic. A 0.014-inch angioplasty guide wire (Medtronic Inc.,
Mississauga, Ontario, Canada) was introduced through a femoral
arteriotomy, advanced to the level of the abdominal aorta and then
withdrawn 3 times and removed. The site was then sealed with surgical
glue, n-butyl cyanoacrylate monomer (Nexaband Veterinary
Products Laboratories, Phoenix, AZ), as previously described (14, 38)
and tissue layers were closed by suture. Mice were given a single
injection of Serp-1 (6 PAI-1
/
mice) or saline (6 PAI-1
/
mice and 6 PAI-1+/+ mice)
immediately after surgery. Mice were then sacrificed and the injured
artery from the iliac bifurcation through the femoral arterial branch
was harvested for histological analysis at 4 weeks follow up.
2-macroglobulin, or
vitronectin, or combinations of proteins and antibodies.
5
M). Cells were cultured with 10% fetal bovine serum,
penicillin (100 units/ml), and streptomycin (100 µg/ml) (Invitrogen).
-actin cDNA (PCR products) reached plateau levels over
36-38 cycles of reaction and were therefore co-amplified using 32 cycles with
-actin as an internal standard (PTC-100 Programmable
Thermal Controller; MJ Research, Watertown, MA) (50, 51). TPA, uPA, PAI-1, uPAR, PARs 1-4, and
-actin cDNA (PCR products) were
measured using a densitometer (Bio-Rad Gel doc 1000) and expressed as a ratio to
-actin (PTC-100 programmable thermal controller, MJ Research) (40, 41). Primers are shown in Table
III. Real time PCR was performed as
described using SYBR green dye and AmpliTaq Gold DNA polymerase in an
ABI Prism 7900HT sequence detection system (AB Applied Biosystems,
Warrington, UK) (39). RT-PCR products were verified by sequencing
cDNA from the gel band (Gel Extraction Kit, Qiagen) with an ABI 377 automated sequencer (PE Applied Biosystems Inc., Mississauga, ON,
Canada). Northern blot analysis was carried out by the
chemiluminescence method (42). RNA was detected (30 µg from HUVEC
cultures treated with control protein or Serp-1) in Northern blots by
chemiluminescence as previously described (43, 44) using
disodium
3-(4-methoxyspiro{1,2-dioxetane-3,2'-(5'-chloro)tricyclo[3.3.1.1]decan}3,7-4-yl
phenyl phosphate substrate (Roche Diagnostics; 0.25 mM
final concentration), and exposed to Kodak XAR-5 film (Sigma) for 20 min at room temperature. Each membrane was probed first for PAI-1 and
then stripped and re-probed with
-actin or tRNA.
Primers for RT-PCR analysis
Western Blot and Enzyme Activity Assay
Arterial sections, from balloon-injured rat ilio-femoral branches at designated time points (0, 12, 24 h and 28 days) after Serp-1 or saline control treatment, were used for the enzyme activity assays and Western blot analysis (45). Arterial sections were homogenized on ice in buffer (20 mM Tris-HCl, 125 mM NaCl, pH 7.4) containing 100 µg/ml phenylmethylsulfonyl fluoride and 10 µg/ml leupeptin proteinase inhibitor (Sigma). Protein concentrations for each sample tested were measured by colorimetric assay (Bio-Rad). For Western analysis, after blocking nonspecific binding sites with blocking solution (5% skim milk, 3% bovine serum albumin, and 0.1% Tween 20 in phosphate-buffered saline) overnight at 4 °C, blots were incubated with 1:800 dilution of rabbit anti-rat PAI-1 or anti-rat tPA (American Diagnostics, Inc.), followed by a 1:100,000 dilution of a monoclonal anti-rabbit IgG (alkaline phosphatase conjugate, Sigma). The color reaction was performed using 5-bromo-4 chloro-3-indoyl phosphate/nitro blue tetrazolium liquid (Bio-Rad).
tPA and uPA activity were measured by chromogenic assay (American Diagnostics), using des-aa-fibrinogen substrate (5 mg/ml, DESAFIBTM, American Diagnostics, Inc.), incubated for 75 min at 37 °C. Plasmin activity was determined by analyzing absorbance at 405 nm on an automated microplate reader (Bio-Rad). For the PAI-1 assay arterial extracts were mixed with 100 µl of tPA substrate (American Diagnostics, Inc.) followed by des-aa-fibrinogen substrate. Absorbance was read at 405 nm.
Statistics
Mean plaque area for individual animals was used for statistical
analyses. Plaque area, enzyme activity, and RT-PCR ratios were assessed
by unpaired Student's t test and analysis of variance. RT-PCR densitometry ratios were compared by paired t test
and analysis of variance. A p value less than 0.05 was
considered significant.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Plaque Growth Is Reduced after Vascular Angioplasty Injury by Serp-1 Infusion
To extend the generality of prior studies in rabbit angioplasty
(11) and rat allograft transplant models (12-14), we tested Serp-1
efficacy for plaque inhibition in a rat angioplasty injury model (Table
I). The plaque growth detected at 28 days follow up after infusion of
control SAA (an inactive variant of Serp-1) (Fig.
1A) was significantly greater
than that following active Serp-1 infusion (Fig. 1B). The
infusion dose given (30 ng/animal) was comparable with prior animal
model studies (11, 12, 14). Serp-1 expressed either from recombinant
CHO cells (Serp-1 CHO) or Serp-1 isolated from a vaccinia recombinant
(Serp-1 VV) inhibited plaque growth to the same extent when compared
with the inactive SAA RCL construct (p < 0.016), or
saline (Fig. 1C) indicating that Serp-1 inhibition of plaque
growth is mediated through serpin activity and that Serp-1 from both
sources behaved similarly. Areas of intimal hyperplasia at 4 weeks
post-injury were predominantly composed of smooth muscle cells with
occasional hemosiderin laden macrophages, as is characteristic of the
rat arterial angioplasty injury model (Fig. 1B) (14).
Thrombosis was only seen occasionally in all groups with no significant
difference detected for any of the treatments tested.
|
Altered Serine Proteinase and Serpin Expression following Rat Angioplasty Injury
Semi-quantitative and real time RT-PCR analysis of rat arterial
sections using altered gene expression after Serp-1 treatment was
analyzed in rat arteries using a balloon-induced vascular angioplasty
injury model (Table I). Semi-quantitative RT-PCR analysis demonstrated
significant changes in mRNA expression in the rat arterial wall at
early time points after angioplasty injury and Serp-1 infusion when
compared with saline control treatment (p < 0.01). A
time course of mRNA expression in representative arterial isolates
after balloon angioplasty injury and treatment with either saline
control or Serp-1 is shown in Fig. 2. A
significant reduction in mRNA for tPA (Fig. 2A,
lanes 2-9) and a relative increase in both PAI-1 (Fig.
2B, lanes 2-9) and uPAR (Fig. 2C, lanes 2-9) at 4 and 12 h after injury were detected in
arterial isolates after Serp-1 treatment when compared with saline
controls (p < 0.01). Real time PCR analysis confirmed
similar significant changes in tPA (Fig.
3A), PAI-1 (Fig.
3B), and uPAR (Fig. 3C) mRNA expression after
angioplasty injury at 4 and 24 h. No significant change in uPA was
detected after injury plus treatment with Serp-1 (not shown).
|
|
Saline control-treated rat arteries following injury had significant
increases in the levels of mRNA expression for tPA
(p < 0.013) and uPAR (p < 0. 0006),
but not PAI-1, at selected time points after angioplasty injury when
compared with the baseline (0 h) time point (Fig. 3,
A-C). SAA control treatment of rat arteries after angioplasty injury had no effect on PAI-1 mRNA levels in the
rat artery compared with Serp-1 treatment (Fig.
4, lanes 1-3). Treatment of
rats with PAI-1 at equivalent, or 10-fold higher, doses to Serp-1
infusion, also had no detected significant effect on PAI-1
up-regulation (Fig. 4, lanes 4 and 5). Normal,
non-injured rat ilio-femoral arterial branches had no demonstrated
change in expression of PAI-1, tPA, or uPAR (not shown) with Serp-1
treatment.
|
In a separate series, the protein levels and enzyme activity for tPA and PAI-1 in the rat ilio-femoral arterial wall were directly measured after angioplasty with Serp-1 or control treatment. A marked reduction in tPA levels, as detected both by immunohistochemical analysis and Western blot analysis (not shown), was observed following Serp-1 treatment. A significant attenuation in tPA enzyme activity increase following injury was also detected in Serp-1-treated rat arteries by 24 h after angioplasty injury (tPA enzyme activity measured by absorbance: for saline-treated arteries = 0.814 ± 0.03, for Serp-1-treated arteries = 0.654 ± 0.022, p < 0.01). PAI-1 inhibitory activity was reduced during the same time frame, and this reduction was attenuated by Serp-1 treatment (PAI-1 inhibitory activity measured by absorbance: for saline-treated arteries = 0.396 ± 0.039, for Serp-1-treated arteries = 0.526 ± 0.023, p < 0.01).
Analysis of Plasminogen Activator and Inhibitor Expression in Cell Culture
We next examined the effect of Serp-1 treatment on selected cell
lines by RT-PCR analysis of several select genes in the host serpin
pathway with potential Serp-1 regulation. PAI-1 mRNA was significantly increased (p < 0.05) in HUVEC cultures
after incubation with Serp-1 when compared with saline controls (Fig.
5, lanes 2 and 3).
Serp-1 treatment produced an increase in PAI-1 mRNA starting at
4 h and continuing to 24 h post-treatment (Fig. 5, lane
3 illustrates 12 h), a time frame similar to that observed for the increase in PAI-1 detected in angioplasty-injured rat arteries
with Serp-1 treatment. In contrast, Serp-1 had no effect on PAI-1
expression in smooth muscle or THP-1 monocytic cell cultures (not
shown). Serp-1 also had no effect on tPA, uPA, protease-activated receptors 1-4 (PARs1-4), or uPAR mRNA expression as measured by RT-PCR analysis in all cell lines tested (not shown). To further confirm this finding, PAI-1 mRNA was also assessed at 24 h
after Serp-1 treatment using Northern blot analysis. Serp-1, but not saline, PAI-1, or SAA (not shown), again significantly increased levels
of PAI-1 mRNA on Northern blot analysis.
|
Inhibition of HUVEC Responses to Serp-1 with Antibodies to uPAR and Vitronectin
Addition of uPAR or vitronectin blocking antibodies alone to HUVEC
cultures had no effect on PAI-1 mRNA levels (Fig. 5, lanes 4 and 6). When antibody to either uPA receptor or
vitronectin was given during Serp-1 treatment of HUVEC cultures,
however, the up-regulation of PAI-1 mRNA produced by Serp-1
treatment was partially attenuated (Fig. 5, lanes 2,
3, 5, and 7). Treatment of HUVEC cells
with both antibodies together completely prevented the Serp-1-mediated
increase in PAI-1 mRNA (Fig. 5, lane 8). Treatment with
antibody to 2-macroglobulin had no effect on
Serp-1-induced up-regulation of PAI-1 expression (not shown). Based on
these results, we examined whether PAI-1 or uPAR might play a role in mediating the anti-inflammatory properties of Serp-1 in knockout mouse models.
Treatment of PAI-1-deficient Mouse Strains with Serp-1 after Vascular Transplant
Based upon the studies reported above demonstrating altered
expression of tPA, PAI-1, and uPAR in rat arteries after treatment with
Serp-1, we tested Serp-1 for inhibition of plaque growth after aortic
allograft transplant in mouse models deficient for PAI-1 or uPAR (Table
II). The aortic allograft transplant model provides a model of chronic
rejection with a marked vascular inflammatory response. The
PAI-1-deficient mouse aortic isograft transplant provided an analysis
of the capacity of Serp-1 to block plaque growth in animals with no
functional PAI-1 expression. The PAI-1-deficient mouse allograft
transplant provided analysis of the relative effects of PAI-1
deficiency in the local donor aortic implant (PAI-1/
to
PAI-1+/+ allografts) and in the recipient aorta and
systemic blood (PAI-1+/+ to PAI-1
/
allografts) and the capacity for Serp-1 to block plaque growth under
both conditions. The uPAR-deficient mouse allograft transplant model
provided an analysis of Serp-1 anti-atherogenic activity in donor aorta
lacking uPAR.
Isograft Aortic Transplants in PAI-1-deficient
(PAI-1/
) Mice--
Aortic sections from isograft
transplants in Balb/c and C57Bl/6 mice with normal PAI-1 expression had
only small areas of intimal hyperplasia 4 weeks after transplant (Fig.
6A). In contrast, PAI-1-deficient mouse aortic isografts had larger areas of plaque development (Fig. 6A). Morphometric analysis of plaque area
demonstrated a significant increase in plaque area in the
PAI-1
/
isografts when compared with either mouse
strains expressing PAI-1 (p < 0.011 for C57Bl/6 and
p < 0.021 for Balb/c mice) (Fig. 6A).
Serp-1 treatment significantly inhibited plaque growth in the
PAI-1
/
isograft transplants (p < 0.025) indicating that up-regulated arterial PAI-1 expression is not
needed for Serp-1-mediated blockade of inflammatory responses and
plaque growth (Fig. 6A). Up-regulation of PAI-1 expression
might, nevertheless, provide additive inhibitory activity.
|
Allograft Aortic Transplants in PAI-1/
Mice--
Aortic allograft transplants also demonstrated increased
plaque development when compared with the isografts (Fig. 6,
B-G). Transplants using PAI-1
/
mice as either the donor (Fig. 6, B and F) or
recipient (Fig. 6, C and G) had larger areas of
plaque development when compared with the isografts. When compared with
aortic allografts from mice where both the donor and the recipient
expressed PAI-1 (PAI-1+/+) (p < 0.04 for
C57BL/6 to Balb/c when compared with C57Bl/6J to Balb/c and
p < 0.06 for Balb/c to C57Bl/6 when compared with Balb/c to C57Bl/6J) plaque area was increased for the PAI-1-deficient mice (Fig. 6, F and G). Of interest was the
finding that when the aorta from PAI-1
/
mice was used
for the donor transplant aortic arterial segment, the plaque area was
larger, although not significant (p < 0.093), than
when the PAI-1
/
mouse was the recipient (Fig. 6,
F and G), suggesting a greater local effect of
aortic serpin expression on transplant vasculopathy development.
Serp-1 Infusion after Aortic Allograft Transplant in
PAI-1/
-deficient Mice--
Serp-1 treatment
reduced plaque area significantly in C57Bl/6J (PAI-1
/
)
to Balb/c (PAI-1+/+) aortic allograft transplants where the
donor aortic section was isolated from the PAI-1
/
mouse
(Fig. 6, D and F, p < 0.0008),
and in Balb/c to C57Bl/6J mice (Fig. 6, E and G,
p = 0.051), where the PAI-1
/
mouse was
the recipient. Serp-1 reduced mean plaque sizes to the range of plaque
sizes observed for isograft transplants. Serp-1 treatment also showed a
trend toward reducing plaque growth after aortic allograft transplant
in PAI-1+/+ mouse models (C57Bl/6 to Balb/c,
p = 0.143 and Balb/c to C57Bl/6, p = 0.057), but this did not reach significance (Fig. 6, F and G). We conclude that Serp-1 retains the ability to mediate
plaque reduction even in the absence of PAI-1 in either the donor or recipient mouse aorta.
Serp-1 Infusion after Femoral Arterial Wire Injury in
PAI-1/
-deficient Mice
A significant increase in plaque area was seen in the
PAI-1-deficient mice when compared with normal PAI-1 expressing C57Bl/6 mice after wire injury. Serp-1 treatment reduced the excess plaque area
in the PAI-1-deficient mice as follows: plaque area saline-treated C57 Bl/6 PAI-1+/+ mice
0.002 ± 0.0009 mm2, saline-treated C57Bl/6J PAI-1
/
mice = 0.028 ± 0.022 mm2, Serp-1 treated
C57Bl/6J PAI-1
/
mice = 0.00009 ± 0.00004 mm2, p < 0.05). This work indicates that
Serp-1 is capable of preventing the increase in plaque seen in mice
lacking PAI-1, both in models of aortic allograft transplant and in
this second model of mechanical, wire-induced arterial injury.
Serp-1 Infusion after Aortic Allograft Transplant from uPAR-deficient Mice
The transplant of aortic allograft segments from uPAR-deficient
(uPAR/
) mice into Balb/c mice had no effect on
generalized plaque growth when compared with uPAR+/+
C57Bl/6 to Balb/c aortic transplant (p = 0.121).
Treatment of mice after uPAR
/
aortic transplant with
Serp-1 at doses proven to inhibit plaque growth in the
PAI-1
/
mouse model no longer blocked plaque growth
(Fig. 7, A-C)
(p = 0.85), indicating that Serp-1 inhibits plaque
growth through mechanisms dependent, at least in part, on the uPAR
complex. Thus we conclude that Serp-1 targets serine proteinases that
utilize uPAR on cells found in the donor transplanted tissue.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We report here that Serp-1 treatment following vascular injury reduces vascular serine proteinase (tPA) expression and induces increased vascular uPAR and serpin (PAI-1) expression levels in the injured arterial wall. In addition, Serp-1 up-regulates expression of PAI-1 in human endothelial cells (HUVEC), specifically through signaling that is dependent upon the uPA receptor and vitronectin. Based upon these findings we postulated that the viral serpin, Serp-1, altered cellular responses by commandeering the mammalian cellular uPA/uPAR serine proteinase response system and altering gene expression. The vascular serpin PAI-1 is known to bind to uPA·uPAR complexes that regulate cellular responses both through extracellular activity involving activation of matrix metalloproteinases and growth factors and enhancing cellular migration and adhesion and also via intracellular signaling through low density lipoprotein-related protein (3-6, 20, 34, 35). The uPA·uPAR·PAI-1 ternary complex effectively blocks uPA·uPAR activity through internalization and breakdown of the uPA·uPAR complex. Vitronectin further enhances PAI-1-mediated inhibition. We have proposed that Serp-1, acting as a native cellular serpin mimic, supplants PAI-1 blocking the uPA·uPAR complex-directed extracellular and intracellular activity.
To test these postulates, we assessed the role of PAI-1 and the uPA receptor in Serp-1-mediated inhibition of inflammation (11-14) in mouse models of aortic transplant. Significantly, we detected inhibition of plaque growth with Serp-1 treatment in PAI-1-deficient, but not in uPAR-deficient, mouse strains. Serp-1 thus successfully exploits the mammalian cellular uPA receptor to alter expression of a key arterial regulator, PAI-1, and to regulate inflammatory cell responses and plaque growth in the arterial wall (3-7, 17, 18, 15, 26). This study provides a definitive demonstration of a viral serpin acting to alter cellular expression and regulation of a mammalian host cell proteinase/receptor system.
Serp-1-mediated up-regulation of PAI-1 was unexpected, but has the potential to amplify inhibition of uPA·uPAR complex-associated cellular invasion in accelerated inflammatory responses. The altered expression of host vascular plasminogen activators and inhibitors is observed beginning as early as 4 h after Serp-1 treatment, suggesting that this amplification of host-mediated regulatory activity plays a role in subsequent anti-inflammatory and anti-atherogenic activity of Serp-1 (Figs. 2 and 3). Our finding that Serp-1 blocked plaque growth in the PAI-1 knockout isografts and after wire injury in PAI-1-deficient mice indicated, however, that Serp-1 anti-inflammatory activity does not depend on increased expression of PAI-1 (Fig. 6A). Increased expression of PAI-1 and uPAR have been previously reported after vascular injury (46-48) and also after injury of other organ systems (48, 49) or invasive carcinoma (50, 51). Our work demonstrates similar increases in control saline-treated animals, but comparison of Serp-1-treated specimens with the saline controls at each time point detected significant alterations in tPA and uPAR gene expression that were greater than the changes in gene expression observed after injury alone.
Dysregulated expression of PAI-1 and tPA induced by Serp-1 is
consistent with a reduction in inflammation and cellular invasion, as
mediated by the uPA·uPAR receptor complex. The inability of the
biochemically inactive Serp-1 mutant, SAA, or PAI-1 itself to
up-regulate PAI-1 gene expression suggests that this was not a
nonspecific reaction to local arterial injury. The finding that Serp-1
altered PAI-1 and uPAR expression, but not expression of protease-activated receptors, PARs 1 to 4 (the main thrombin
receptors), suggests that Serp-1 activity is specifically mediated
through the cell surface uPA/uPAR system, and not circulating thrombin or the clotting cascade. Also, the ability of Serp-1 to trigger effects
in human endothelial cells is of great significance and suggests that
Serp-1 initiates a non-species-specific response in the arterial wall
via a conserved regulatory mechanism. The inhibition of PAI-1 increase
by the combined action of blocking antibodies to uPAR and vitronectin
is also consistent with mediation of Serp-1 anti-inflammatory activity
through the uPA/uPAR system. Vitronectin is known to bind and stabilize
the uPA·uPAR·PAI-1 complex and thereby enhance PAI-1 inhibitory
activity (35-37, 50). The mechanism for the increase in uPAR
expression in the arterial wall by Serp-1 remains to be explained, but
is likely to be of functional significance closely linked to the
inflammatory process, as well as acting on clot regulatory systems to
prevent excessive vascular thrombosis. The proinflammatory cytokines,
such as tumor necrosis factor, up-regulate tPA and PAI-1 expression
(3-7, 17-20, 27). In turn, the plasminogen activators and plasmin
proteolytically activate "pro-forms" of the matrix
metalloproteinase enzymes to their active state, which serves to
accelerate the break down of connective tissue and allows cellular
invasion at sites of injury and inflammation. The pro-form of
TACE, the tumor necrosis factor activator, is similarly activated by
plasminogen activators (2-7, 27). Transforming growth factor ,
basic fibroblast growth factor, and epidermal growth factor are all
activated by serine proteinase enzymes in the thrombolytic cascade
(specifically, the plasminogen activators, Ref. 23).
Correlation has recently been demonstrated between early
inflammatory activity secondary to surgical injury and ischemia and with late transplant vasculopathy development (51-54). The angioplasty injury model provides a model for assay of serpin effects on simple mechanical (balloon mediated) vascular injury. The results of these
studies established a basis for examining anti-inflammatory mechanisms
of Serp-1 on vascular injury and plaque growth after transplant
(12-14) using mouse knockout models. Transplant is associated with a
vigorous inflammatory response, providing a challenging system for
testing serpin-mediated anti-inflammatory activity. Of further interest
is the apparent greater plaque inhibitory activity of Serp-1 when given
to mice with aortic transplants lacking PAI-1 (PAI-1/
donor aorta, Fig. 6, A-G) when compared with
transplant of PAI-1 expressing aorta into a PAI-1-deficient
(PAI-1
/
) recipient mouse aorta. In line with this
observation was the fact that plaque area in the transplanted artery
was larger when the donor aorta lacked PAI-1 expression. Surprisingly
serpin-mediated reductions in plaque development would appear to have
more profound local effects, intrinsic to the transplanted arterial
wall, rather than a generalized or systemic effect. Confirmation of
this observation will require further study.
Viral immunomodulating factors such as Serp-1 are believed to mimic
mammalian cell factors, targeting central regulatory activities in the
immune and inflammatory systems (8-14). The lack of Serp-1 anti-atherogenic activity in the uPAR/
mouse aortic
transplant model provides excellent confirmation for the necessity of
the uPA receptor for Serp-1-mediated anti-inflammatory activity. This
finding was in marked contrast to the capacity of Serp-1 to reduce
plaque growth in the PAI-1
/
aortic allograft and
isograft transplants. Analysis of the pathways through which viral
serpins, and specifically Serp-1, block inflammatory responses and
intimal hyperplasia after vascular injury will define serpin-regulated
inflammatory responses to vascular injury. Viral cytokine and cytokine
receptor mimicking proteins (termed virokines and viroceptors) provide
highly effective inhibitors that block inflammatory responses at very
low concentrations, estimated at picomolar to nanomolar amounts (11,
12, 14, 55).
This work is the first study demonstrating that a secreted viral
serpin, Serp-1, is capable of regulating vascular cellular inflammatory
responses to injury through altered cell serine proteinase, serpin and
receptor responses, effectively hijacking the native mammalian cell
response system. The extraordinary efficacy of these inhibitors at low
pharmacological concentrations is predicted to provide new insights
into central regulatory mechanisms in the inflammatory cascades.
![]() |
ACKNOWLEDGEMENT |
---|
We thank Joan Fleming for help in typing and collating this manuscript. Viron Therapeutics Inc. supplied the CHO cell-purified Serp-1 protein used for these studies.
![]() |
FOOTNOTES |
---|
* This work was supported by research grants from the Heart and Stroke Foundation of Ontario and the Canadian Institutes of Health Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom all correspondence should be addressed: John P. Robarts' Research Institute, University of Western Ontario, 100 Perth Dr., P.O. Box 5015, London, Ontario N6A 5K8, Canada. Tel.: 519-685-8300 (ext. 34071); Fax: 519-663-3789; E-mail: arl@robarts.ca.
Published, JBC Papers in Press, March 10, 2003, DOI 10.1074/jbc.M209683200
2 R. Zhong, personal communication.
3 Viron Therapeutics, Inc., personal communication.
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: tPA, tissue-type plasminogen activator; uPA, urokinase-type plasminogen activator; uPAR, urokinase-type plasminogen activator receptor; CHO, Chinese hamster ovary; SAA, Serp-1 reactive center loop mutant; RT, reverse transcriptase; HUVEC, human umbilical vein endothelial.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. |
Libby, P.,
Ridker, P. M.,
and Maseri, A.
(2002)
Circulation
105,
1135-1143 |
2. |
Ross, R.
(1999)
N. Engl. J. Med.
340,
115-126 |
3. | Blasi, F. (1997) Trends Immunol. Today 18, 415-417 |
4. | Stefansson, S., Haudenschild, C. C., and Lawrence, D. A. (1998) Trends Card. Med. 8, 175-180[CrossRef] |
5. | Estreicher, A., Muhlhauser, J., Carpentier, J. L., Orci, L., and Vassalli, J. D. (1990) J. Cell Biol. 111, 783-792[Abstract] |
6. | Deng, G., Curridan, S., Wang, S., Rosenberg, S., and Loskutoff, D. J. (1996) J. Cell Biol. 134, 1563-1571[Abstract] |
7. |
Silverman, G. A.,
Bird, P. I.,
Carrell, R. W.,
Church, F. D.,
Coughlin, P. B.,
Gettins, P. G. W.,
Irving, J. A.,
Lomas, D. A.,
Luke, C. J.,
Moyer, R. W.,
Pemberton, P. A.,
Remold-O'Donnell, E.,
Salvesen, G. S.,
Travis, J.,
and Whisstock, J. C.
(2001)
J. Biol. Chem.
276,
33293-33296 |
8. | Turner, P. C., and Moyer, R. W. (2001) Am. Soc. Microbiol. News 67, 201 |
9. | Upton, C., Macen, J. L., Wishart, D. S., and McFadden, G. (1990) Virology 170, 618-631 |
10. |
Nash, P.,
Whitty, A.,
Handwerker, J.,
Macen, J.,
and McFadden, G.
(1998)
J. Biol. Chem.
273,
20982-20991 |
11. |
Lucas, A. R.,
Liu, L. Y.,
Macen, J.,
Nash, P.,
Dai, E.,
Stewart, M.,
Graham, K.,
Etches, W.,
Boshkov, L.,
Nation, P. N.,
Lundstrom Hobman, M.,
and McFadden, G.
(1996)
Circulation
94,
2890-2900 |
12. |
Miller, L. W.,
Dai, E.,
Nash, P.,
Liu, L.,
Icton, C.,
Klironomos, D.,
Fan, L.,
Nations, P. N.,
Zhong, R.,
McFadden, G.,
and Lucas, A.
(2000)
Circulation
101,
1598-1605 |
13. | Hausen, B., Boeke, K., Berry, G. J., and Morris, R. E. (2001) Transplantation (Baltimore) 72, 364-368 |
14. | Lucas, A., Dai, E., Liu, L., Guan, H., Nash, P., McFadden, G., and Miller, L. (2000) J. Heart Lung Transplant. 19, 1029-1038[CrossRef][Medline] [Order article via Infotrieve] |
15. | Stefansson, S., and Lawrence, D. A. (1996) Nature 383, 441-443[CrossRef][Medline] [Order article via Infotrieve] |
16. | Jackson, C. L., and Reidy, M. A. (1992) Ann. N. Y. Acad. Sci. 667, 141-150[Abstract] |
17. | Zalai, C. V., Nash, P., Dai, E., Liu, L., and Lucas, A. (2002) in Cardiovascular Plaque Rupture (Brown, D. L., ed) , pp. 447-482, Marcel Dekker, Inc., New York |
18. |
Reidy, M. A.,
Irvin, C.,
and Lindner, V.
(1996)
Circ. Res.
78,
405-414 |
19. |
Chang, A. W.,
Kuo, A.,
Barnathan, E. S.,
and Okada, S. S.
(1998)
Arterioscler. Thromb. Vasc. Biol.
18,
1855-1860 |
20. |
Chavakis, T.,
Kanse, S. M.,
Yutzy, B.,
Lijnen, H. R.,
and Preissner, K. T.
(1998)
Blood
91,
2305-2312 |
21. | Germer, M., Kanse, S. M., Kirkegaard, T., Kjoller, L., Felding-Habermann, B., Goodman, S., and Preissner, K. T. (1998) Eur. J. Biochem. 253, 669-674[Abstract] |
22. |
Lijnen, H. R.,
Van Hoef, B.,
Lupu, F.,
Moons, L.,
Carmeliet, P.,
and Collen, D.
(1998)
Arterioscler. Thromb. Vasc. Biol.
18,
1035-1045 |
23. |
Falcone, D. J.,
McCaffrey, T. A.,
Haimovitz-Friedman, A.,
Vergilio, J. A.,
and Nicholson, A. C.
(1993)
J. Biol. Chem.
268,
11951-11958 |
24. | Gettins, P., Patston, P. A., and Schapira, M. (1992) Hematol. Oncol. Clin. N. Am. 6, 1393-1408[Medline] [Order article via Infotrieve] |
25. | Forsyth, K. D., Talbot, V., and Beckman, I. (1994) Clin. Exp. Immunol. 95, 277-282[Medline] [Order article via Infotrieve] |
26. |
Carmeliet, P.,
and Colen, D.
(1995)
FASEB J.
9,
934-938 |
27. | Carmeliet, P., Schoonjans, L., Kieckans, L., Ream, B., Degen, J., Bronson, R., De Vos, R., van den Oord, J. J., Collen, D., and Mulligen, R. C. (1994) Nature 368, 419-424[CrossRef][Medline] [Order article via Infotrieve] |
28. |
Carmeliet, P.,
Moons, L.,
Lijnen, R.,
Janssens, S.,
Lupu, F.,
Collen, D.,
and Gerard, R. D.
(1997)
Circulation
96,
3180-3191 |
29. |
Falkenberg, M.,
Tom, C.,
DeYoung, M. B.,
Wen, S.,
Linnemann, R.,
and Dichek, D. A.
(2002)
Proc. Natl. Acad. Sci.
99,
10665-10670 |
30. |
Moons, L.,
Shi, C.,
Ploplis, V.,
Plow, E.,
Haber, E.,
Collen, D.,
and Carmeliet, P.
(1998)
J. Clin. Invest.
102,
1788-1797 |
31. |
Levi, M.,
Moons, L.,
Bouche, A.,
Shapiro, S. D.,
Collen, D.,
and Carmeliet, P.
(2001)
Circulation
103,
2014-2020 |
32. |
Sjoland, H.,
Eitzman, D. T.,
Gordon, D.,
Westrick, R.,
Nabel, E. G.,
and Ginsburg, D.
(2000)
Arterioscler. Thromb. Vasc. Biol.
20,
846-852 |
33. |
Ploplis, V. A.,
and Castellino, F. J.
(2001)
Ann. N. Y. Acad. Sci.
936,
466-468 |
34. | Seiffert, D., and Loskutoff, D. J. (1991) Biochim. Biophys. Acta 1078, 23-30[Medline] [Order article via Infotrieve] |
35. |
Stefansson, S.,
Muhammad, S.,
Cheng, X. F.,
Battey, F. D.,
Strickland, D. K.,
and Lawrence, D. A.
(1998)
J. Biol. Chem.
273,
6358-6366 |
36. |
Stoop, A. A.,
Lupu, F.,
and Pannekoek, H.
(2000)
Arterioscler. Thromb. Vasc. Biol.
20,
1143-1149 |
37. | Koulack, J., McAlister, V. C., Giacomantonio, C. A., Bitter-Suermann, H., MacDonald, A. S., and Lee, T. D. (1995) Microsurgery 16, 110-113[Medline] [Order article via Infotrieve] |
38. |
Liu, L. Y.,
Lalani, A.,
Dai, E.,
Seet, B.,
Macauley, C.,
Singh, R.,
Fan, L.,
McFadden, G.,
and Lucas, A.
(2000)
J. Clin. Invest.
105,
1613-1621 |
39. |
Rocnik, E. F.,
Chan, B. M. C.,
and Pickering, J. G.
(1998)
J. Clin. Invest.
101,
1889-1898 |
40. |
Sestini, R.,
Orlandoo, C.,
Zentilin, L.,
Lami, D.,
Gelmini, S.,
Pinzani, P.,
Giacca, M.,
and Pazzagli, M.
(1995)
Clin. Chem.
41,
826-832 |
41. |
Bustin, S. A.
(2000)
J. Mol. Endocrinol.
25,
169-193 |
42. |
Barka, T.,
and van der Noen, H.
(1993)
J. Histochem. Cytochem.
41,
1863-1867 |
43. | Manejwala, F. M., Logan, C. Y., and Schultz, R. M. (1991) Dev. Biol. 144, 301-308[Medline] [Order article via Infotrieve] |
44. |
Nagai, N.,
De Mol, M.,
Lijnen, H. R.,
Carmeliet, P.,
and Collen, D.
(1999)
Circulation
99,
2440-2444 |
45. | Sawa, H., Sobel, B. E., and Fujii, S. (1993) Circ. Res. 73, 671-680[Abstract] |
46. |
Hasenstab, D.,
Forough, R.,
and Clowes, A. W.
(1997)
Circ. Res.
80,
490-496 |
47. |
Strauss, B. H.,
Lau, H. K.,
Bowman, K. A.,
Sparkes, J.,
Chisholm, R. J.,
Garvey, M. B.,
Fenkell, L. L.,
Natarajan, M. K.,
Singh, I.,
and Teitel, J. M.
(1999)
Circulation
100,
1616-1622 |
48. |
Nagai, N.,
De Mol, M.,
Lijnen, H. R.,
Carmeliet, P.,
and Collen, D.
(1999)
Circulation
99,
2440-2444 |
49. | Saxne, T., Lecander, I., and Geborek, P. (1993) J. Rheumatol. 20, 91[Medline] [Order article via Infotrieve] |
50. | Gladson, C. L., Stewart, J. E., Olman, M. A., Chang, P.-L., Schnapp, L. M., Grammer, J. R., and Benveniste, E. N. (2000) Neurosci. Lett. 283, 157-161[CrossRef][Medline] [Order article via Infotrieve] |
51. | Yamamoto, M., Ikeda, K., Ohshima, K., Tsugu, H., Kimura, H., and Tomonaga, M. (1997) Cancer Res. 57, 2799-2805[Abstract] |
52. |
McMahon, G. A.,
Petitclerc, E.,
Steffansson, S.,
Smith, E.,
Wong, M. K. K.,
Westrick, R. J.,
Ginsburg, D.,
Brooks, P. C.,
and Lawrence, D. A.
(2001)
J. Biol. Chem.
276,
33964-33968 |
53. | Miller, L., Kobashigawa, J., Valantine, H., Ventura, H., Hauptman, P., O'Donnell, J., Wiedermann, J., and Yeung, A. (1995) J. Heart Lung Transplant. 14, S227-S234[Medline] [Order article via Infotrieve] |
54. | Hayry, P., Myllarniemi, M., and Aavik, E. (1996) Transplant. Proc. 28, 2337-2338[Medline] [Order article via Infotrieve] |
55. | Bot, I., von der Thusen, J. H., Lucas, A., Donners, M. M. P. C., Heeneman, S., Fekkes, M. L., Kuper, J., Daemen, M. J. A. P., van Berkel, J. C., and Biessen, E. A. L. (2002) in Preclinical Evaluation of Gene Therapeutic Approaches to Atherosclerosis, Towards a Sustained Anti-inflammatory Therapy (von der Thusen, J. H., ed) , pp. 11-19, Print Partners Ipstamp, Emschede, The Netherlands |